Vrije extractie van nucleïnezuren door middel van de magnetische kralenmethode

Cell free DNA (cfDNA) was first discovered in human peripheral blood, and in the past decades cfDNA has been extracted from urine, cerebrospinal fluid and pleural fluid. cfDNA-based liquid biopsy technology greatly reduces the pain and risk for patients due to its non-invasive nature, and the analysis of the results is based on gene sequencing, thus providing accurate and convincing information. The results are analyzed based on gene sequencing technology, so the analysis is accurate and the information is comprehensive and convincing.

Comparative advantages of liquid biopsy

In comparison, CRISPR-Cas system-based detection technology is more expensive and can only detect and analyze a single sequence, which is low throughput and difficult to achieve comprehensive detection. Although the serum marker-based detection method is easy to operate, it is only effective for some genetic diseases, which limits its scope of application, and the specificity of serum marker detection has certain limitations.

Importance of cfDNA in medical testing

It has been shown by numerous studies that cfDNA derived from fetal and tumor tissues has greatly contributed to the development of the field of noninvasive prenatal diagnosis and liquid biopsy and other potential applications.

Fragment size of cfDNA and disease association

Different fragment sizes of cfDNA exist in human peripheral blood. cfDNA is not only an important biomolecular target for the detection of tumors, fetal development and autoimmune diseases, but also provides relevant information about the donor genome, which is of great significance for the detection and analysis of diseases.

Specificity of cfDNA fragment size

The cfDNA in the plasma of pregnant women derived from fetus, tumor-related cfDNA in the plasma of tumor patients and cfDNA in autoimmune deficiency patients are different from those in the plasma of healthy people in terms of fragment size.

Shanghai Lingjun Bio’s cfDNA Extraction Technology

Shanghai Lingjun Bio serum/plasma free DNA extraction reagent and ccfDNA extraction reagent realize the enrichment of short fragment DNA in human body fluids by magnetic bead method. Combining this high-resolution DNA fragment extraction technology with sequencing and other technologies holds the promise of solving the problems of low signal-to-noise ratio and poor sensitivity of samples in non-invasive prenatal diagnosis, liquid biopsy and early screening for immunodeficiency-type diseases. The use of the magnetic bead method will also have a driving effect on improving sequencing library building efficiency and cost savings, which will enable sequencing-based early disease screening to enter a deeper field and contribute more to the improvement of public health.

Introductie van leveranciers

Shanghai Lingjun Biotechnologie Co., Ltd. werd opgericht in 2016 dat een professionele fabrikant is van biomagnetische materialen en reagentia voor nucleïnezuurextractie.

We hebben een rijke ervaring in de extractie en zuivering van nucleïnezuren, eiwit zuivering, cel scheiding, chemiluminescentie en andere technische gebieden.

Onze producten worden op veel gebieden veel gebruikt, zoals medische testen, genetische testen, universitair onderzoek, genetische veredeling, enzovoort. Wij leveren niet alleen producten, maar kunnen ook OEM ondernemen, ODM, en andere behoeften. Als u gerelateerde behoeften heeft, neem dan gerust contact met ons op via sales01@lingjunbio.com.